EXHIBIT 10.5
[ASTRAZENECA LETTERHEAD]
Xxxx Xxxxxxx
CIMA Laboratories Inc
29 August 2002
Our Ref: Your Ref: Tel: Fax:
Agt/Comm/Cima/Lic & Supply x00 0000 000000 x00 0000 000000
Dear Xxxx
LICENSE AGREEMENT DATED 28 MAY 1999 BETWEEN CIMA LABORATORIES INC AND IPR
PHARMACEUTICALS INC (THE "AGREEMENT")
We note that the Agreement historically refers to OraSolv Technology in relation
to the production of fastmelt tablets and are aware that under the resulting
Supply Agreement, DuraSolv Technology is being utilized to produce fastmelt
tablets. We therefore would appreciate it if you could sign and return a copy of
this letter to us to confirm that the definition of OraSolv Technology in the
Agreement includes the DuraSolv Technology used at present (plus any associated
improvements as defined in the Agreement) in the manufacture of Zomig Rapimelt
tablets.
Many thanks for your assistance in this clarification.
Yours sincerely,
Xxx Tinebo
Supply Chain & Logistics
Signed and Accepted on behalf of CIMA Laboratories Inc by
/s/ Xxxx X. Xxxxxxx 30 Aug, 2002
-------------------------------------------------------
Xxxx Xxxxxxx
